Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Печать: 0893-9675
ISSN Онлайн: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2019031108
pages 259-267

The Association of Type 2 Diabetes and Site-Specific Cancers: Linking Mechanisms

Leila Hosseini
Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Farbod Alinezhad
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Uldouz Kharazi
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
Reza Badalzadeh
Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Physiology, Faculty of Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Краткое описание

Diabetes mellitus (DM) and cancer are global health problems that constitute a major portion of spending for every health system. Epidemiological and experimental studies have demonstrated the interrelationship between type 2 DM (T2DM) and cancer in various tissues such as pancreas, colon, endometrium, ovary, and breast. The exact biological mechanisms by which DM may cause an increased risk of cancer are incompletely understood. The reason for a correlation may be attributed to different elements, including common risk factors between cancer and diabetes and possibly the biological links between the pathophysiology of the two diseases. Insulin resistance, hyperinsulinemia, hyperglycemia, increased levels of insulin-like growth factor, and the chronic inflammation associated with diabetes may increase cancer incidence and mortality in patients with T2DM. The aim of the current study is to review the literature on this subject to shed light on the possible relationships between T2DM and some site-specific cancers.


  1. Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: A 90-year perspective. Postgrad Med J. 2016;92(1084):3-9.

  2. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):737-835.

  3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015;65(2):87-108.

  4. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Endocrine Prac. 2011;17(4):616-28.

  5. Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: What is the connection? Mount Sinai J Med. 2010;77(2):197-213.

  6. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: A consensus report. Cancer J Clin. 2010 Jul;60(4):207-21.

  7. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R, Barnighausen T, Davies J, Vollmer S. Global economic burden of diabetes in adults: Projections from 2015 to 2030. Diabetes Care. 2018 May;41(5):963-70.

  8. Najafi M, Farajnia S, Mohammadi M, Badalzadeh R, Asl NA, Baradaran B, Amani M. Inhibition of mitochondrial permeability transition pore restores the cardioprotection by postconditioning in diabetic hearts. J Diabetes Metabol Disord. 2014 Dec;13(1):106.

  9. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocrine Rel Cancer. 2009;16(4): 1103-23.

  10. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist. 2010;15(6):548-55.

  11. Papa V, Pezzino V, Costantino A, Belfiore A, Giuffrida D, Frittitta L, Vannelli GB, Brand RI, Goldfine ID, Vigneri R. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990 Nov;86(5):1503-10.

  12. Stefansdottir G, Zoungas S, Chalmers J, Kengne AP, Knol MJ, Leufkens HG, Patel A, Woodward M, Grobbee DE, De Bruin ML. Intensive glucose control and risk of cancer in patients with type 2 diabetes. Diabetologia. 2011 Jul;54(7):1608-14.

  13. Tseng C-H, Tseng F-H. Diabetes and gastric cancer: The potential links. World J Gastroenterol. 2014;20(7):1701.

  14. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 1976;36(12): 4595-601.

  15. Yousefi B, Faghfoori Z, Samadi N, Karami H, Ahmadi Y, Badalzadeh R, Shafiei-Irannejad V, Majidinia M, Ghavimi H, Jabbarpour M. The effects of Ramadan fasting on endo-thelial function in patients with cardiovascular diseases. Eur J Clin Nutr. 2014 Jul;68(7):835.

  16. da Costa Rocha AR. At the intersection of diabetes and cancer: The role of angiogenesis and inflammation [disser-tation]. Porto (Portugal): Abel Salazar da Universidade do Porto; 2017.

  17. Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, Palli D, Tumino R, Mattiello A, Vineis P, Nieters A, Linseisen J. Glycosylated hemoglobin and risk of colorectal cancer in men and women. The European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3108-15.

  18. Rzepka-Gorska I, Bedner R, Cymbaluk-Ploska A, Chudecka-Glaz A. Serum adiponectin in relation to endometrial cancer and endometrial hyperplasia with atypia in obese women. Eur J Gynaecol Oncol. 2008;29(6):594-7.

  19. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.

  20. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-87.

  21. Lecarpentier Y, Claes V, Vallee A, Hebert J-L. Interactions between PPAR gamma and the canonical Wnt/beta-catenin pathway in type 2 diabetes and colon cancer. PPAR Res. 2017;2017:5879090.

  22. Vasconcelos-Dos-Santos A, Loponte HF, Mantuano NR, Oliveira IA, De Paula IF, Teixeira LK, de-Freitas-Junior JC, Gondim KC, Heise N, Mohana-Borges R, Morgadoiaz JA. Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway. Oncogenesis. 2017 Mar;6(3):e306.

  23. Lucena MC, Carvalho-Cruz P, Donadio JL, Oliveira IA, de Queiroz RM, Marinho-Carvalho MM, Sola-Penna M, de Paula IF, Gondim KC, McComb ME, Costello CE. Epithelial mesenchymal transition induces aberrant glyco-sylation through hexosamine biosynthetic pathway activation. J Bio Chem. 2016 Jun 17;291(25):12917-29.

  24. Uzozie A, Nanni P, Staiano T, Grossmann J, Barkow- Oesterreicher S, Shay JW, Tiwari A, Buffoli F, Laczko E, Marra G. Sorbitol dehydrogenase overexpression and other aspects of dysregulated protein expression in human pre-cancerous colorectal neoplasms: A quantitative proteomics study. Mol Cell Proteom. 2014 May;13(5):1198-218.

  25. Holst S, Stavenhagen K, Balog CI, Koeleman CA, McDonnell LM, Mayboroda OA, Verhoeven A, Mesker WE, Tollenaar RA, Deelder AM, Wuhrer M. Investigations on aberrant glycosylation of glycosphingolipids in colorectal cancer tissues using liquid chromatography and matrix-assisted laser desorption time-of-flight mass spec-trometry (MALDI-TOF-MS). Mol Cell Proteom. 2013 Nov 1;12(11):3081-93.

  26. Onitsuka K, Shibao K, Nakayama Y, Minagawa N, Hirata K, Izumi H, Matsuo KI, Nagata N, Kitazato K, Kohno K, Itoh H. Prognostic significance of UDP-N- acetyl-a-D-galactosamine:polypeptideN-acetylgalactosaminyl-transferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer Sci. 2003 Jan;94(1):32-6.

  27. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342.

  28. Jacobs ET, Kohler LN, Kunihiro AG, Jurutka PW. Vitamin D and colorectal, breast, and prostate cancers: A review of the epidemiological evidence. J Cancer. 2016;7(3):232.

  29. Bao B, Wang Z, Li Y, Kong D, Ali S, Banerjee S, Ahmad A, Sarkar FH. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim Biophys Acta. 2011 Apr;1815(2):135-46.

  30. Kornmann M, Maruyama H, Bergmann U, Tangvoranuntakul P, Beger HG, White MF, Korc M. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res. 1998 Oct 1;58(19):4250-4.

  31. Teng JA, Wu SG, Chen JX, Li Q, Peng F, Zhu Z, Qin J, He ZY. The activation of ERK1/2 and JNK MAPK signaling by insulin/IGF-1 is responsible for the development of colon cancer with type 2 diabetes mellitus. PLoS One. 2016 Feb 22;11(2):e0149822.

  32. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform ex-pression in FFPE breast tumors. Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):108-15.

  33. Martin SD, McGee SL. Metabolic reprogramming in type 2 diabetes and the development of breast cancer. J Endocrinol. 2018;237(2):R35-46.

  34. Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, Holst J. Adipocyte lipolysis links obesity to breast cancer growth: Adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metabol. 2017 Dec;5(1):1.

  35. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-KB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci. 2004 Jul 6;101(27):10137-42.

  36. Alvero AB. Recent insights into the role of NF-kappaB in ovarian carcinogenesis. Genome Med. 2010;2(8):56.

  37. Tanaka Y, Kobayashi H, Suzuki M, Hirashima Y, Kanayama N, Terao T. Genetic down-regulation of preg-nancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis. Int J Cancer. 2004;109(3):336-47.

  38. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A, Kavanagh JJ, Lee JH, Zhang W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell inva-sion. Mol Cancer. 2005 Dec;4(1):7.

  39. Grossmann M. Low testosterone in men with type 2 di-abetes: Significance and treatment. J Clin Endocrinol Metabol. 2011;96(8):2341-53.

  40. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124(6):1398-403.

  41. Lutz SZ, Hennenlotter J, Scharpf MO, Sailer C, Fritsche L, Schmid V, Kantartzis K, Wagner R, Lehmann R, Berti L, Peter A. Androgen receptor overexpression in prostate cancer in type 2 diabetes. Mol Metabol. 2018 Feb;8:158-66.

  42. Pandini G, Mineo R, Frasca F, Roberts CT, Marcelli M, Vigneri R, Belfiore A. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res. 2005 Mar;65(5):1849-57.

  43. Weihua Z, Lathe R, Warner M, Gustafsson J-A. An endo-crine pathway in the prostate, ERp, AR, 5a-androstane-3p, 17P-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci. 2002;99(21):13589-94.

  44. Rovira-Llopis S, Banuls C, de Maranon AM, Diaz-Morales N, Jover A, Garzon S, Rocha M, Victor VM, Hernandez-Mijares A. Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients. Free Rad Biol Med. 2017 Jul 1;108:155-62.

  45. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, MacIsaac RJ, Clarke S, Zajac JD, Jerums G. Low testos-terone levels are common and associated with insulin re-sistance in men with diabetes. J Clin Endocrinol Metabol. 2008 May 1;93(5):1834-40.

  46. Tseng C-H. Obesity paradox: Differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus. Atherosclerosis. 2013;226(1):186-92.

  47. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 2012;12(3):159.

  48. Giovannucci E. Insulin, insulin-like growth factors and colon cancer:A review ofthe evidence. J Nutr. 2001;131(11): 3109S-20S.

  49. Yoon JM, Son KY, Eom CS, Durrance D, Park SM. Pre-existing diabetes mellitus increases the risk of gastric cancer: A meta-analysis. World J Gastroenterol. 2013; 19(6):936.

  50. Luo J, Xiang Y, Xu X, Fang D, Li D, Ni F, Zhu X, Chen B, Zhou M. High glucose-induced ROS production stimulates proliferation of pancreatic cancer via inactivating the JNK pathway. Oxidat Med Cell Longev. 2018;2018(10):1-10.

  51. Tiffon C. Histone deacetylase inhibition restores expression of hypoxia-inducible protein NDRG1 in pancreatic cancer. Pancreas. 2018;47(2):200-7.

  52. Han L, Ma Q, Li J, Liu H, Li W, Ma G, Xu Q, Zhou S, Wu E. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS One. 2011 Nov 8;6(11):e27074.

  53. Li W, Ma Z, Ma J, Li X, Xu Q, Duan W, Chen X, Lv Y, Zhou S, Wu E, Ma Q. Hydrogen peroxide mediates hyperglycemia-induced invasive activity via ERK and p38 MAPK in human pancreatic cancer. Oncotarget. 2015 Oct 13;6(31):31119.

  54. Yan J, Zhang Z, Shi H. HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci. 2012;69(1):115-28.

  55. Li J, Ma J, Han L, Xu Q, Lei J, Duan W, Li W, Wang F, Wu E, Ma Q, Huo X. Hyperglycemic tumor microenvironment induces perineural invasion in pancreatic cancer. Cancer Biol Ther. 2015 Jun 3;16(6):912-21.

  56. Ma J, Jiang Y, Jiang Y, Sun Y, Zhao X. Expression of nerve growth factor and tyrosine kinase receptor A and correlation with perineural invasion in pancreatic cancer. J Gastroenterol Hepatol. 2008;23(12):1852-9.

Articles with similar content:

Type 2 Diabetes and Cancer: An Overview of Epidemiological Evidence and Potential Mechanisms
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 3
Farhad Hosseinpanah, Asghar Ghasemi, Parvin Mirmiran, Zahra Bahadoran
Type 2 Diabetes and Cancer: The Nitric Oxide Connection
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 3
Asghar Ghasemi, Khosrow Kashfi, Parvin Mirmiran, Zahra Bahadoran
Advances in Molecular Biomarkers for Gastric Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Tang-Hui Zheng, Bayasi Guleng, Jun-Lin Zhao
Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.33, 2016, issue 4
Munira Momin, Chintan Bhavsar, Sankalp A. Gharat
Is Tissue Cross-Talk Important in Cancer Cachexia?
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 3
Neil Johns, Kenneth C. H. Fearon, C. A. Greig